Biogen agrees to $900 mln drug kickback settlement, U.S. Justice Dept says

Pharmaceutical company Biogen agrees to pay $900 million to settle kickback claims

Pharmaceutical company Biogen Inc. has agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to recommend its multiple sclerosis drugs, causing false submission claims to Medicare and Medicaid.

Pharmaceutical company agrees to settle for $900M to resolve allegations it provided kickbacks to physicians and submitted false claims

Pharmaceutical company agrees to settle for $900M to resolve allegations it provided kickbacks to physicians and submitted false claims

Biogen pays $900M to settle doctor kickback allegations

The agreement announced Monday settles a whistleblower lawsuit brought by a former Biogen employee.

Biogen pays $900M to settle doctor kickback allegations

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade them to prescribe its multiple sclerosis drugs

Biogen pays $900M to settle doctor kickback allegations

BOSTON (AP) — Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs, federal prosecutors said.

Massachusetts-based Biogen pays $900M to settle allegations

Biogen has agreed to resolve allegations that it violated federal law by paying kickbacks to doctors.